Navigation Links
UCB Announces Positive Results From Phase II Clinical Trial of Investigational Anti-Epilepsy Drug Brivaracetam
Date:12/3/2007

t fully controlled despite treatment with one or two other antiepileptic drugs. The third study is a randomized, double-blind, placebo-controlled trial with flexible dosing designed to evaluate the safety and tolerability of brivaracetam in patients with uncontrolled partial onset or primary generalized seizures. First results of these studies are expected in mid 2009.

About Brivaracetam: Brivaracetam has distinct pharmacological differences as well as having some structural similarity to the AED Keppra(R) (levetiracetam). In preclinical studies brivaracetam was shown to have a 10- fold higher affinity for synaptic vesicle protein 2A (SV2A) than Keppra(R). Brivaracetam also has inhibitory activity at neuronal voltage-dependent sodium channels whose abnormal function is understood to contribute to electrical discharges associated with seizures. These differences may explain brivaracetam's antiepileptic activity, clinical efficacy and tolerability.

About Epilepsy: Epilepsy is a chronic neurological disorder affecting more than 2.5 million Americans regardless of race, age or sex. Between 70-80% of individuals are successfully treated with one of the more than 20 antiepileptic drugs now available. However, 20-30% of patients have either intractable or uncontrolled seizures or have significant adverse side effects secondary to medication, highlighting the ongoing need for the development of new antiepileptic drugs.

About Keppra(R) in the U.S.: Keppra(R) tablets and oral solution are indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy, myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. Keppra(R) injection is indicated as adjunctive therapy in the treatment of myoclonic seizures in JME
'/>"/>

SOURCE UCB, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Becker's Hospital Review has published ... and Health Systems With Great Heart Programs." , ... nation in cardiovascular and thoracic healthcare. Many have ... have received recognition from reputable sources for top-of-the-line ... Becker's Hospital Review has compiled this list and ...
(Date:10/31/2014)... October 31, 2014 TheHardwareCity.com is the ... winter. Many quality electric space heaters are available at ... superior Broan-Nutone Big Heat 1500w portable electric space heater. ... available at TheHardwareCity.com, offers an energy efficient way to ... The ceramic heating elements produce 1500 Watts, ensuring a ...
(Date:10/31/2014)... PA (PRWEB) October 31, 2014 Fundraising support ... are greater gains than losses. At noon on Monday, November ... Memorial Hospital (SSMH), greater than 20 Susquehanna Health (SH) ... locks to raise awareness and funds for the new Cancer ... shave participants’ heads for this act of love and support ...
(Date:10/31/2014)... central to life. The last stage, when two daughter ... the dawn of cell biology in the Victorian era. ... to study this final step, when the dividing cell ... name given to this process by those early biologists, ... of a highly active and organized series of events. ...
(Date:10/31/2014)... October 31, 2014 Springboard Biodiesel, ... its small scale BioPro™ biodiesel processors, announced on ... further improve the performance and efficiency of small-scale ... GL95/MC12/BD380 trio will recover more than 99% ... with the glycerin by-product produced while making biodiesel. ...
Breaking Medicine News(10 mins):Health News:Becker's Hospital Review Names 100 Hospitals, Health Systems With Great Heart Programs 2Health News:Becker's Hospital Review Names 100 Hospitals, Health Systems With Great Heart Programs 3Health News:Becker's Hospital Review Names 100 Hospitals, Health Systems With Great Heart Programs 4Health News:Big Heat 1500w Electric Space Heater Now Available at TheHardwareCity.com 2Health News:Susquehanna Health Soldiers + Sailors Memorial Hospital Razing Heads to Fight Cancer 2Health News:Cell division, minus the cells 2Health News:Cell division, minus the cells 3Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 2Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 3
... UCLA team develops device giving patients freedom of movement, better ... An automated artificial kidney that can be worn on ... the insulin pump is to diabetes patients. , The automated, ... to a paper in the current issue of Clinical ...
... SUCCESS, N.Y., July 25 Anthony Shih,M.D., ... Officer and Vice President,of Strategic Planning, after ... a,national foundation committed to improving U.S. health ... on Health Care Quality,Improvement and Efficiency., ...
... therapy may be due to genetic factors , , FRIDAY, ... the long-held belief that the hepatitis C virus (HCV) ... HIV patients are treated with highly active antiretroviral therapy ... HIV-infected drug users are also infected with HCV. Intravenous ...
... Authority offers patients consumers tips and encourages them ... HARRISBURG, Pa., July 25 The Pennsylvania,Patient ... which,is a national effort to encourage patients and ... asking questions and learning,everything they can about their ...
... of Defense and Federal Agencies in, the execution ... four-day, multi-agency collaborative training event designed to ... complex incident response scenarios. Dataline is ... infrastructure for medical use during the exercise., NORFOLK, ...
... Ill., July 25 Sagent Pharmaceuticals, Inc.,a ... it,has launched amiodarone HCl injection, USP, a ... prophylaxis of frequently recurring,ventricular fibrillation and hemodynamically ... heart beat.,Sagent,s amiodarone HCl injection will be ...
Cached Medicine News:Health News:IPRO Welcomes Back Anthony Shih as Chief Quality Officer, Strategic Planning Lead 2Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3Health News:Dataline Announces Participation in Operation Golden Phoenix 2Health News:Dataline Announces Participation in Operation Golden Phoenix 3Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3
(Date:10/31/2014)... 2014 According to ... Management Market by Product (Data Management, Anesthesia, Surgical, ... (Software, Services), Delivery Mode (Web-Based, On-Premise) - ... provides a detailed overview of major drivers, ... strategies impacting the global market along with ...
(Date:10/31/2014)... Oct. 31, 2014  Digirad Corporation (Nasdaq: DRAD) today announced ... (Nasdaq: PDII ), a healthcare commercialization services ... to acquire the company.  Digirad calls ... a transaction and to operate in the ordinary course ... take on additional debt, on acquisitions or other extraordinary ...
(Date:10/31/2014)... , Oct. 31, 2014  Semler Scientific, ... emerging medical risk assessment company that develops patented ... and evaluating chronic diseases, today reported financial results ... September 30, 2014. "In the ... Doug Murphy-Chutorian , M.D., chief executive officer ...
Breaking Medicine Technology:Operating Room Management Market Worth $4,551.1 Million by 2019 2Operating Room Management Market Worth $4,551.1 Million by 2019 3Operating Room Management Market Worth $4,551.1 Million by 2019 4Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 2Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 3Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 4Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 5Semler Reports Third Quarter 2014 Financial Results 2Semler Reports Third Quarter 2014 Financial Results 3
... Findings Reinforce March of Dimes Message: Start Taking a ... 11 Women who take folic acid supplements for ... cut their risk of having a premature baby by ... online journal, PLOS Medicine.The study links pre-conceptional folate supplementation ...
... Announces Positive Top Line Results of its Clinical Study ... Mass., May 11 Logical Therapeutics, Inc (Logical), a ... treat diseases associated with inflammation, today announced that Peter ... has been elected to the Company,s Board of Directors. ...
Cached Medicine Technology:Taking Folic Acid for a Year Before Pregnancy May Reduce Risk of Preterm Birth 2Logical Therapeutics Appoints Peter A. Lankau as CEO and Director 2Logical Therapeutics Appoints Peter A. Lankau as CEO and Director 3Logical Therapeutics Appoints Peter A. Lankau as CEO and Director 4
Cordis DUCOR Catheters are available in a broad variety of French sizes and configurations. These catheters combine an atraumatic tip with either a braided or non-braided body....
The advanced center-of-the-arc system allows an infinite choice of trajectories. The system's lightweight durable frame provides accuracy, simplicity, patient mobility and accessibility....
The CRW system epitomizes simplicity, quality assurance, and versatility....
Used for complex diagnostic and interventional procedures....
Medicine Products: